# Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

> **NCT06491563** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Brii Biosciences Limited** · enrollment: 150 (estimated)

## Conditions studied

- For Treatment of Chronic Hepatitis B Virus Infection

## Interventions

- **BIOLOGICAL:** BRII-179
- **DRUG:** BRII-835 (VIR-2218)
- **BIOLOGICAL:** PEG-IFNα

## Key facts

- **NCT ID:** NCT06491563
- **Lead sponsor:** Brii Biosciences Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-06
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06491563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06491563, "Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06491563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*